ALK‑positive lung cancer presents urgent challenges — from rapid disease progression to treatment resistance driven by co‑mutations and tumor persistence. Understanding these mechanisms is vital to improving survival and developing therapies that go beyond current approaches.
This grant call supports translational research on early progression, metastatic patterns, and tumor microenvironment reprogramming. Priority areas include persister cell mechanisms, co‑mutations and ALK variants, metabolic vulnerabilities, and novel therapies such as vaccines and cell‑based treatments.
Applicants must be affiliated with non‑profit academic or research institutions, with patient advocates included in the research design. Both U.S. and international researchers at any career stage are eligible.
📊 Support available — up to $300,000 over two years, with at least half dedicated to translational science.
If you already have an active fundsforNGOs Premium Membership, simply log in to access complete details, including eligibility criteria, application guidelines, and deadlines — all in one place.
Not yet renewed your Premium Membership account? Renew Today & Keep Your Premium Edge
